Malaria vaccine based on self-assembling protein nanoparticles. 2015

Peter Burkhard, and David E Lanar
a Institute of Materials, Science and Department of Molecular and Cell Biology , University of Connecticut , Storrs , CT 06269 , USA.

Despite recent progress with GSK's RTS,S malaria vaccine, there remains a desperate need for an efficient malaria vaccine. We have used a repetitive antigen display technology to display malaria specific B cell and T cell epitopes in an effort to design a vaccine against Plasmodium falciparum malaria. Our protein sequence when assembled into a nanoparticle induces strong, long-lived and protective immune responses against infection with the parasite. We are confident that the clinical trials with our most developed vaccine candidate will show good protection in a controlled human malaria infection trial.

UI MeSH Term Description Entries
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000913 Antibodies, Protozoan Immunoglobulins produced in a response to PROTOZOAN ANTIGENS. Protozoan Antibodies
D000953 Antigens, Protozoan Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered. Protozoan Antigens
D016778 Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. Plasmodium falciparum Malaria,Malaria, Plasmodium falciparum
D017780 Malaria Vaccines Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents. Malaria Vaccine,Malarial Vaccine,Malarial Vaccines,Vaccine, Malaria,Vaccine, Malarial,Vaccines, Malaria,Vaccines, Malarial
D053758 Nanoparticles Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging. Nanocrystalline Materials,Nanocrystals,Material, Nanocrystalline,Materials, Nanocrystalline,Nanocrystal,Nanocrystalline Material,Nanoparticle
D018984 Epitopes, T-Lymphocyte Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen. T-Cell Epitopes,T-Lymphocyte Epitopes,T-Cell Epitope,T-Lymphocyte Epitope,Epitope, T-Cell,Epitope, T-Lymphocyte,Epitopes, T Lymphocyte,Epitopes, T-Cell,T Cell Epitope,T Cell Epitopes,T Lymphocyte Epitope,T Lymphocyte Epitopes
D018985 Epitopes, B-Lymphocyte Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen. B-Cell Epitopes,B-Lymphocyte Epitopes,B-Cell Epitope,B-Lymphocyte Epitope,B Cell Epitope,B Cell Epitopes,B Lymphocyte Epitope,B Lymphocyte Epitopes,Epitope, B-Cell,Epitope, B-Lymphocyte,Epitopes, B Lymphocyte,Epitopes, B-Cell

Related Publications

Peter Burkhard, and David E Lanar
September 2018, Nanomedicine (London, England),
Peter Burkhard, and David E Lanar
November 2013, Journal of nanobiotechnology,
Peter Burkhard, and David E Lanar
October 2012, Journal of nanobiotechnology,
Peter Burkhard, and David E Lanar
January 2024, International journal of molecular sciences,
Peter Burkhard, and David E Lanar
January 2019, International journal of molecular sciences,
Peter Burkhard, and David E Lanar
November 2022, Bioconjugate chemistry,
Peter Burkhard, and David E Lanar
December 2010, Microbial cell factories,
Peter Burkhard, and David E Lanar
March 2018, Journal of controlled release : official journal of the Controlled Release Society,
Peter Burkhard, and David E Lanar
November 2021, International journal of molecular sciences,
Copied contents to your clipboard!